Furthermore, the head-to-head comparison of two AML surface proteins, CD123 and CD33, showed that CD123-ADCs display an efficacity comparable to that of CD33-ADCs, but a better safety profile in nonhuman primates [80]. This evidence concerns the gene IL3RA and acute myeloid leukemia.